Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis
A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells (AlloJoin®) Therapy for Knee Osteoarthritis.
Wuxi Cellular Biopharmaceutical Group Ltd.
520 participants
Feb 28, 2025
INTERVENTIONAL
Conditions
Summary
Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Therapy
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use
Sodium Hyaluronate administrated for intra-articular use
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06570291